The fraction of activated N-methyl-d-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
Open Access
- 21 May 2008
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 115 (8) , 1119-1126
Abstract
Excessive N-methyl-d-aspartate (NMDA) receptor activation is widely accepted to mediate calcium-dependent glutamate excitotoxicity. The uncompetitive, voltage-dependent NMDA receptor antagonist memantine has been successfully used clinically in the treatment of neurodegenerative dementia and is internationally registered for the treatment of moderate to severe Alzheimer′s disease. Glutamate release inhibitors (GRIs) may also be promising for the therapy of some neurodegenerative diseases. During the clinical use of GRIs, it could be questioned whether there would still be a sufficient number of active NMDA receptors to allow any additional effects of memantine or similar NMDA receptor antagonists. To address this question, we determined the fraction of NMDA receptors contributing to postsynaptic events in the presence of therapeutically relevant concentrations of the GRI riluzole (1 μM) using an in vitro hippocampal slice preparation. We measured the charge transfer of pharmacologically isolated excitatory synaptic responses before and after the application of the selective, competitive NMDA receptor antagonist D-AP5 (100 μM). The fraction of activated NMDA receptors under control conditions did not differ from those in the presence of riluzole. It is therefore likely that NMDA receptor antagonists would be able to exert additional therapeutic effects in combination therapy with GRIs.Keywords
This publication has 56 references indexed in Scilit:
- The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2006
- Diverse mechanisms of antiepileptic drugs in the development pipelineEpilepsy Research, 2006
- Current pharmacological management of amyotropic lateral sclerosis and a role for rational polypharmacyExpert Opinion on Pharmacotherapy, 2004
- Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic StrokeCerebrovascular Diseases, 1998
- Riluzole AnesthesiaAnesthesiology, 1996
- Glutamate Antagonists in Amyotrophic Lateral SclerosisCNS Drugs, 1996
- RiluzoleCNS Drug Reviews, 1996
- A Randomized, Double‐Blind, Placebo‐Controlled Ascending Dose Tolerance Study of 619C89 in Acute StrokeAnnals of the New York Academy of Sciences, 1995
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivoNeuroscience Letters, 1992